Literature DB >> 9286775

"Refractoriness" of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts.

D J Ross1, A Marchevsky, M Kramer, R M Kass.   

Abstract

The clinical significance of an isolated "lymphocytic bronchiolitis/bronchitis" (grade B) as detected in transbronchoscopic biopsy specimens (TBB) is unclear. We therefore have reviewed the spirometric responses associated with isolated grade B diagnoses and contrasted them with episodes of "acute cellular rejection" (grade A); the latter are manifested by "perivascular lymphocytic infiltration." Because lymphocytic bronchiolitis/ bronchitis is considered a nonspecific histologic pattern that may be observed with either allograft rejection or respiratory infections, episodes were analyzed with respect to the presence (grade B [+] CMV) or absence (grade B [-] CMV) of cytomegalovirus infection. The maximum forced expiratory volume in 1 second (FEV1) during the preceding 3 months was used as a baseline for computing percent change in FEV1 coincident with transbronchoscopic biopsies (delta %FEV1 PRE) and maximum values obtained during the 3 months subsequent to specific therapies (delta %FEV1 POST). All episodes of acute cellular rejection (grades A1 to 4) and symptomatic lymphocytic bronchiolitis/bronchitis (grade B) were treated with "pulsed-dose" methylprednisolone, whereas intravenous ganciclovir was administered to patients at risk for recrudescence of cytomegalovirus. Between March 1, 1989, and September 1, 1995, 366 TBB procedures were performed for clinical indications in 57 lung transplant recipients. Histologic diagnoses with acceptable serial spirometric values included grade A1 (n = 9), grade A2 (n = 27), grade A3 (n = 2), grade B(-)CMV (n = 25) and grade B(+)CMV (n = 9). The delta %FEV1 PRE coincident with TBB were not statistically different for the different histologic groups. For grade A1, delta %FEV1 PRE was -14.6% +/- 5.2% (X +/- SEM); A2, -7.6% +/- 1.8%; B(-)CMV, -14.8% +/- 3.9%; and B(+)CMV, -14.8% +/- 2.3%. After treatment, the delta %FEV1 POST, relative to baseline values, were for grade A1, -8.8% +/- 7.1%, A2, +0.26% +/- 2.6%; B(-)CMV, -12.0% +/- 3.8%; and B(+)CMV, -6.2% +/- 2.8%. The delta %FEV1 POST values after pulsed methylprednisolone were significantly greater for histologic grade A2 than grade B(-)CMV (unpaired Student's t test, P < 0.01; 95% confidence interval for the difference of means: 3.34% to 21.2%). Grade A2 rejection was associated with spirometric improvement to within 10% of baseline values in 52% of episodes; whereas with grade B(-)CMV, this salutary response was observed in only 32% of episodes. Bronchiolitis obliterans syndrome stage 1b developed in 13 of 20 (65%) recipients, approximately 7.9 +/- 3.4 months after detection of histologic grade B and 21.2 +/- 9.5 months after transplantation. We conclude that the relative "refractoriness" of histologic grade B most likely reflects a continuum of bronchiolitis obliterans after lung transplantation and, hence, may warrant different immunosuppressive strategies. Furthermore, spirometric decrement associated with acute cellular rejection (grade A) may be ameliorated, but often not completely reversed, after pulsed methylprednisolone. We speculate that surveillance TBB may prove rewarding by enabling an earlier detection of these histologic diagnoses before the development of physiologic impairment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286775

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

Review 1.  Human and murine obliterative bronchiolitis in transplant.

Authors:  John F McDyer
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 2.  The role of the immune system in lung transplantation: towards improved long-term results.

Authors:  Ramsey R Hachem
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

3.  Gene Expression Profiling of Bronchoalveolar Lavage Cells During Aspergillus Colonization of the Lung Allograft.

Authors:  S Samuel Weigt; Xiaoyan Wang; Vyacheslav Palchevskiy; Naman Patel; Ariss Derhovanessian; Michael Y Shino; David M Sayah; Joseph P Lynch; Rajan Saggar; David J Ross; Bernie M Kubak; Abbas Ardehali; Scott Palmer; Shahid Husain; John A Belperio
Journal:  Transplantation       Date:  2018-06       Impact factor: 4.939

4.  Plasma Donor-derived Cell-free DNA Levels Are Increased During Acute Cellular Rejection After Lung Transplant: Pilot Data.

Authors:  David Sayah; S Samuel Weigt; Allison Ramsey; Abbas Ardehali; Jeff Golden; David J Ross
Journal:  Transplant Direct       Date:  2020-09-24

Review 5.  Complement-mediated microvascular injury leads to chronic rejection.

Authors:  Mohammad A Khan; Mark R Nicolls
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

6.  Protein-DNA array-based identification of transcription factor activities differentially regulated in obliterative bronchiolitis.

Authors:  Ming Dong; Xin Wang; Hong-Lin Zhao; Yu-Xia Zhao; Ya-Qing Jing; Jing-Hua Yuan; Yi-Jiu Guo; Xing-Long Chen; Ke-Qiu Li; Guang Li
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

7.  Usefulness of gene expression profiling of bronchoalveolar lavage cells in acute lung allograft rejection.

Authors:  S Samuel Weigt; Xiaoyan Wang; Vyacheslav Palchevskiy; Xinmin Li; Naman Patel; David J Ross; John Reynolds; Pali D Shah; Lara A Danziger-Isakov; Stuart C Sweet; Lianne G Singer; Marie Budev; Scott Palmer; John A Belperio
Journal:  J Heart Lung Transplant       Date:  2019-05-07       Impact factor: 10.247

Review 8.  Chronic allograft dysfunction.

Authors:  Christiane Knoop; Marc Estenne
Journal:  Clin Chest Med       Date:  2011-06       Impact factor: 2.878

9.  Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation.

Authors:  Kiran K Khush; Iwijn De Vlaminck; Helen Luikart; David J Ross; Mark R Nicolls
Journal:  ERJ Open Res       Date:  2021-01-25

10.  Clinical Validation of a Plasma Donor-derived Cell-free DNA Assay to Detect Allograft Rejection and Injury in Lung Transplant.

Authors:  Justin P Rosenheck; David J Ross; Mena Botros; Alexander Wong; Jonathan Sternberg; Yen-An Chen; Nathan Liang; Amy Baer; Ebad Ahmed; Ryan Swenerton; Bernhard G Zimmermann; Gordon Fehringer; Zachary P Demko; Michael Olymbios; Paul R Billings; Brian C Keller
Journal:  Transplant Direct       Date:  2022-03-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.